The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

RATIONALE The Cystic Fibrosis Foundation Patient Registry (CFFPR) is an ongoing patient registry study that collects longitudinal demographic, clinical, and treatment information about persons with cystic fibrosis (CF) in the United States. CF is a life-shortening genetic disorder that occurs in approximately 1 in 3,500 births in the United States. High-quality observational data is important for clinical research, quality improvement, and clinical management. OBJECTIVES To describe the data collection, patient population, and key limitations of the CFFPR. METHODS Inclusion criteria for the CFFPR include diagnosis with CF or a CFTR-associated disorder, care at an accredited care center program, and provision of informed consent. Data from clinic visits and hospitalizations are collected through a secure website. Loss to follow-up and generalizability were examined using several methods. The accuracy of CFFPR data was evaluated with an audit of 2012 CFFPR data compared to the medical record. MEASUREMENTS AND MAIN RESULTS Since 1986, the CFFPR contains the records of 48,463 individuals with CF. Participation among individuals seen at accredited care centers is high, and loss to follow-up is low. An audit of 2012 CFFPR data suggests that the CFFPR contains 95% of clinic visits and 90% of hospitalizations found in the medical record for these patients, and nearly all of the audited fields were highly accurate. CONCLUSIONS Registries such as the CFFPR are important tools for research, clinical care, and tracking incidence, mortality and population trends.

[1]  T. Liou,et al.  Lung transplantation and survival in children with cystic fibrosis. , 2007, The New England journal of medicine.

[2]  C. Penland,et al.  Cystic fibrosis foundation: achieving the mission. , 2009, Respiratory care.

[3]  S. Somers Improving chronic care. , 2002, Health affairs.

[4]  D. Sanders,et al.  Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening , 2015, Pediatrics.

[5]  C. Kaye Newborn Screening Fact Sheets , 2006, Pediatrics.

[6]  D. Sanders,et al.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis , 2015, Thorax.

[7]  S. Grosse,et al.  Variation in immunoreactive trypsinogen concentrations among michigan newborns and implications for cystic fibrosis newborn screening , 2011, Pediatric pulmonology.

[8]  R. Parad,et al.  Newborn screening showing decreasing incidence of cystic fibrosis. , 2008, The New England journal of medicine.

[9]  A. Thompson,et al.  Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California. , 2013, The Journal of molecular diagnostics : JMD.

[10]  J. Zieleński,et al.  Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. , 2005, The Journal of pediatrics.

[11]  Vicky A Legrys,et al.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. , 2008, The Journal of pediatrics.

[12]  R. Parad,et al.  Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. , 2004, Pediatrics.

[13]  S. Stanojevic,et al.  A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts. , 2016, Journal of clinical epidemiology.

[14]  M. Rosenfeld,et al.  Opportunities and pitfalls of registry data for clinical research. , 2013, Paediatric respiratory reviews.

[15]  Mats Lundström,et al.  Use of 13 disease registries in 5 countries demonstrates the potential to use outcome data to improve health care's value. , 2012, Health affairs.

[16]  Emily A. Knapp,et al.  Children and young adults with CF in the USA have better lung function compared with the UK , 2014, Thorax.

[17]  C. Goss,et al.  Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. , 2004, American journal of respiratory and critical care medicine.

[18]  F. Lorey,et al.  Birth prevalence of disorders detectable through newborn screening by race/ethnicity , 2012, Genetics in Medicine.

[19]  J. Nick,et al.  Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. , 2010, American journal of respiratory and critical care medicine.

[20]  S. Fitzsimmons The changing epidemiology of cystic fibrosis. , 1994, Current problems in pediatrics.

[21]  A. Dias,et al.  Sleep pathology characterization in sickle cell disease: Case–control study , 2015, Pediatric pulmonology.

[22]  Peter Davey,et al.  A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  R. Laessig,et al.  Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. , 2005, The Journal of pediatrics.

[24]  Laura Marrow,et al.  Improving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center Network , 2014, BMJ quality & safety.

[25]  Douglas G Altman,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.

[26]  Douglas G Altman,et al.  [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. , 2007, Gaceta sanitaria.

[27]  J. Wakefield,et al.  Fine particulate matter exposure and initial Pseudomonas aeruginosa acquisition in cystic fibrosis. , 2015, Annals of the American Thoracic Society.

[28]  C. Goss,et al.  The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement , 2014, BMJ quality & safety.

[29]  J Rick Turner,et al.  Characterization of Missing Data in Clinical Registry Studies , 2015, Therapeutic innovation & regulatory science.